You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Harvard Business School
Express Scripts
Colorcon
Moodys

Last Updated: April 8, 2020

DrugPatentWatch Database Preview

Leadiant Biosci Inc Company Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for LEADIANT BIOSCI INC, and when can generic versions of LEADIANT BIOSCI INC drugs launch?

LEADIANT BIOSCI INC has seven approved drugs.

There are three US patents protecting LEADIANT BIOSCI INC drugs.

There are four patent family members on LEADIANT BIOSCI INC drugs in four countries and four supplementary protection certificates in three countries.

Summary for Leadiant Biosci Inc
International Patents:4
US Patents:3
Tradenames:6
Ingredients:5
NDAs:7

Drugs and US Patents for Leadiant Biosci Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Leadiant Biosci Inc CARNITOR levocarnitine SOLUTION;ORAL 018948-002 Apr 27, 1988 DISCN No No   Start Trial   Start Trial
Leadiant Biosci Inc CARNITOR levocarnitine INJECTABLE;INJECTION 020182-001 Dec 16, 1992 AP RX Yes Yes 6,335,369   Start Trial   Start Trial
Leadiant Biosci Inc ABELCET amphotericin b INJECTABLE, LIPID COMPLEX;INJECTION 050724-001 Nov 20, 1995 RX Yes Yes   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Leadiant Biosci Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Leadiant Biosci Inc ABELCET amphotericin b INJECTABLE, LIPID COMPLEX;INJECTION 050724-001 Nov 20, 1995 6,406,713   Start Trial
Leadiant Biosci Inc MATULANE procarbazine hydrochloride CAPSULE;ORAL 016785-001 Approved Prior to Jan 1, 1982 3,520,926   Start Trial
Leadiant Biosci Inc ABELCET amphotericin b INJECTABLE, LIPID COMPLEX;INJECTION 050724-001 Nov 20, 1995 5,616,334   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for Leadiant Biosci Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1919458 SPC/GB14/019 United Kingdom   Start Trial PRODUCT NAME: CYSTEAMINE; REGISTERED: UK EU/1/13/861 20130910
1919458 300649 Netherlands   Start Trial PRODUCT NAME: CYSTEAMINE; REGISTRATION NO/DATE: EU/1/13/861/001-002 20130910
1919458 C300649 Netherlands   Start Trial PRODUCT NAME: CYSTEAMINE; REGISTRATION NO/DATE: EU/1/13/861/001-002 20130906
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Medtronic
Boehringer Ingelheim
Express Scripts
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.